Treatment Action Group (TAG) elected three new members to its Board of Directors in May 2024. Board President Ivy Kwan Arce said, "TAG is reinvigorating its Board in alignment with our vision, mission, and values.
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
We're pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.
On behalf of the Global Tuberculosis Community Advisory Board (TB CAB), we're excited to announce a call for new member applications.
Treatment Action Group (TAG) calls on Danaher to lower the price of GeneXpert tests for tuberculosis (TB) and other diseases to $5 each in accordance with publicly available evidence of the cost of manufacturing and to commit to public transparency of the cost audit of Xpert MTB/RIF Ultra.
TAG's emergency plea to our allies at MSF to preserve its life-saving and world-changing MSF Access Campaign (Campaign for Access to Essential Medicines) — we need them now more than ever!
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 2nd meeting of the WHO Director-General’s TB Vaccine Accelerator Council in Geneva Switzerland.
TAG delivered an intervention at the UN High-Level Meeting on Antimicrobial Resistance (AMR) Multistakeholder Hearing, calling on member states to incorporate drug-resistant TB (DR-TB) in the political declaration as a key component of AMR response.
On May 15, 2024, TAG hosted this webinar on the TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing.
Rifapentine, an off-patent drug that's been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.